Parkinsons

Instead of focusing only on the brain, this work studies the gut–brain connection, an area gaining increasing attention in Parkinson’s research. By understanding how abnormal signals may travel from the digestive system to the brain, researchers hope to identify earlier and more effective intervention points.

Squalamine is an oral compound that has shown promising results in laboratory and animal studies. It appears to interfere with harmful protein buildup associated with Parkinson’s disease. Importantly, it is being studied as a potential disease-slowing therapy, not just a symptom treatment.

No. This research does not claim a cure. The goal is more realistic and responsible: to slow disease progression, protect remaining nerve function, and improve quality of life for people living with Parkinson’s.

The research is actively moving from laboratory studies toward carefully designed clinical trials in humans. These trials are essential to confirm safety and determine whether the approach offers meaningful benefit.

Purpose Forward funding helps bridge the gap between promising science and patient-ready clinical studies. Depending on federal grant outcomes, funds will either:

• Expand and strengthen a large clinical trial, or
• Launch a smaller pilot study to generate critical early data

In both cases, funds are used to accelerate progress responsibly.

Yes. Leading organizations — including the Michael J. Fox Foundation for Parkinson’s Research — actively support research into the gut–brain connection and the role of harmful proteins in Parkinson’s disease. This project builds on that same scientific direction by advancing a specific, promising therapy toward clinical testing.

Yes — in early-stage studies. An oral form of this therapy has already been tested in Parkinson’s patients and shown to be safe and biologically active. What has not yet been proven — and what this research aims to determine — is whether it can slow disease progression, which requires carefully designed clinical trials.

Yes. It builds on scientific directions supported by major Parkinson’s research organizations and early human studies, and focuses on the next critical step: determining whether this approach can meaningfully slow the disease.

Success is measured using established Parkinson’s disease assessments, safety monitoring, and patient-reported outcomes. This ensures progress is based on real data—not hype.

Parkinson’s disease causes enormous suffering, and progress has been slow. Purpose Forward supports research that is:

• Scientifically credible
• Focused on real-world impact
• Transparent and accountable

This initiative aligns with our commitment to measured impact, human dignity, and meaningful progress.

Yes. Purpose Forward receives regular updates from the research team and shares progress milestones so donors understand how their support is advancing the work.